!DOCTYPE html> ACTTION

April 24, 2013: New ACTTION Consortium on Peripheral Neuropathy


A new ACTTION consortium has been established as a result of an FDA public workshop on “Clinical development programs for disease-modifying agents for peripheral neuropathy” that was held on February 11-12, 2013. The CONsortium on Clinical Endpoints and Procedures for Peripheral neuropathy Trials (CONCEPPT) will be co-chaired by Dr. Roy Freeman of Harvard University. On the basis of the FDA public workshop and subsequent discussions, CONCEPPT will undertake various activities, including the development of new efficacy outcome measures for disease-modifying peripheral neuropathy trials and convening meetings and preparing consensus recommendations for clinical trial designs of disease-modifying treatments.